Marathon Asset Management to acquire Kaléo for $310m.

Marathon Asset Management, an investment firm, agreed to acquire Kaléo, a privately held pharmaceutical company, for $310m. “The sales trajectory of Kaléo has been impressive, and we view the company as a platform for growth,” said Dr. Evan Bedil, Head of Healthcare at Marathon. We plan to leverage the company’s strong portfolio of intellectual property, its leading reputation among allergists and its experienced management team, to pursue multiple avenues of growth in the coming years,” Evan Bedil, Marathon Head of Healthcare.